plaque-analysis
(4)
Elucid wants to know what your plaque is made of
A narrowed artery tells only part of the story. Elucid turns CT scans into tissue-informed plaque maps, betting that cardiology needs a closer look at the trouble inside the wall.
Cleerly
Cleerly is a Denver-based digital healthcare company using FDA-cleared artificial intelligence to analyze coronary CT scans and non-invasively measure plaque, stenosis and the likelihood of ischemia in the heart's arteries. Founded in 2017 by cardiologist James K. Min, the company builds machine-learning software that turns a routine CCTA scan into a quantitative, vessel-by-vessel picture of coronary artery disease - aiming to catch atherosclerosis earlier and help physicians prevent heart attacks rather than react to them.
James K. Min
James K. Min is the founder and CEO of Cleerly, a Denver-based digital health company using AI to analyze coronary CT scans and detect atherosclerosis long before a heart attack strikes. A board-certified cardiologist who spent two decades in academic medicine, Min left a professorship at Weill Cornell and the directorship of the Dalio Institute of Cardiovascular Imaging to build a company that could deliver personalized, plaque-based heart evaluation at scale. He has authored more than 500 peer-reviewed papers, led landmark cardiac imaging trials, and raised hundreds of millions to push a shift from population-based cardiology toward individualized care.
Heartflow
Heartflow is a Silicon Valley medical technology company that uses AI and computational fluid dynamics to turn a standard coronary CT scan into a personalized, color-coded 3D model of a patient's heart. Its FFRCT, Plaque and RoadMap analyses help cardiologists diagnose and manage coronary artery disease non-invasively, reducing the need for invasive angiograms. Founded in 2007 and headquartered in San Francisco, Heartflow has analyzed hundreds of thousands of patients across more than 1,500 U.S. hospitals and went public on the Nasdaq (HTFL) in August 2025.